In this episode, Martin reflects on a short position in Amazon that moved against him and discusses the lessons he took away from the trade. He also explains why he believes Meta may represent an attractive buying opportunity, shares his views on Reddit and Nvidia, and revisits his bearish thesis on SanDisk, examining each company's valuation, competitive position, and the factors influencing his current investment outlook.

In this episode, Martin discusses the market events surrounding Leopold Aschenbrenner's reported liquidation and explains how he believes Ken Griffin and Citadel became involved in absorbing or trading the affected positions. He examines market structure, institutional trading, liquidity, and risk management, sharing his perspective on how large firms respond to forced liquidations and the lessons investors can draw from these events.

In this episode, Martin discusses receiving a margin call from JPMorgan following market events related to Leopold Aschenbrenner's reported liquidation. He explains how leverage, margin requirements, and counterparty risk can affect investors during periods of heightened volatility, while sharing his perspective on risk management, portfolio construction, and the lessons traders can learn from highly leveraged positions.

In this episode, Martin discusses the principles he believes are essential for building long-term wealth through trading. He explains his approach to identifying high-probability opportunities, managing risk, sizing positions, and maintaining discipline, while emphasizing the importance of probability, patience, and continuous learning in developing a successful trading strategy.

In this episode, Martin discusses what he believes is Meta's primary business weakness and how it could affect the company's long-term outlook. He also revisits his bearish thesis on SanDisk, examines the cyclical nature of the memory semiconductor industry through Micron, and analyzes Nektar Therapeutics, sharing his perspective on each company's valuation, competitive position, and potential risks and opportunities.

In this episode, Martin explains the balance sheet metric he believes provides particularly valuable insight into a company's financial health and long-term prospects. He discusses how to interpret financial statements, evaluate capital allocation, and identify strengths and weaknesses in a business, sharing his perspective on why this measure plays an important role in fundamental stock analysis.

In this episode, Martin discusses the reported liquidation of a $20 billion hedge fund and the market conditions that may have contributed to the event. He examines the impact of leverage, risk management, liquidity, and portfolio construction, sharing his perspective on how large investment firms can become vulnerable during periods of market stress and the lessons traders can draw from high-profile liquidations.

In this episode, Martin joins TBPN to discuss the liquidation of investor Leopold and the market events that led up to it. He examines the role of leverage, risk management, and position sizing, while explaining the importance of situational awareness when navigating volatile markets. The conversation also explores trading psychology, portfolio management, and the lessons investors can draw from high-profile liquidations.

In this episode, Martin explains why he believes a particular investment presents a compelling opportunity and the reasoning behind that view. He also analyzes Kioxia and Microsoft, discussing their businesses, competitive positioning, valuation, and long-term prospects. The episode concludes with a lesson on property, plant, and equipment (PP&E), where he explains how to interpret these balance sheet assets and why they matter when evaluating companies.

In this episode, Martin reacts to an FDA advisory committee meeting involving Capricor Therapeutics, sharing his perspective on the discussion, the evidence presented, and the committee's deliberations. He examines the clinical data, regulatory considerations, and potential implications for the company's development program and investment outlook.